Eastern Health, Victoria, Australia; Research & Molecular Development, Victorian Infectious Diseases Reference Laboratory, 10 Wreckyn St, North Melbourne, VIC 3051, Australia.
Curr Opin Virol. 2013 Oct;3(5):495-500. doi: 10.1016/j.coviro.2013.08.006. Epub 2013 Sep 7.
Antiviral therapy for chronic hepatitis B (CHB) has improved the outcome of patients. However, due to the multiple selection pressures of different nucleos(t)ide analogue, drug resistant HBV variants have emerged. Because of the arrangement of overlapping reading frames in HBV genome, these variants not only have clinical implications such as drug resistance, but also the potential to pose public health issues via vaccine escape. Whilst emergence of these variants cannot be prevented, careful selection and institution of the appropriate rescue anti viral therapy based on high genetic barrier and high potency should minimize this outcome.
抗病毒治疗慢性乙型肝炎（CHB）改善了患者的预后。然而，由于不同核苷（酸）类似物的多种选择压力，耐药的乙型肝炎病毒变异体已经出现。由于乙型肝炎病毒基因组中重叠阅读框的排列，这些变异体不仅具有耐药性等临床意义，而且还有可能通过逃避疫苗而对公共卫生造成影响。虽然这些变异体的出现无法预防，但根据高遗传屏障和高效能，谨慎选择和实施适当的挽救性抗病毒治疗，应将这种结果降到最低。
